Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Medical Oncology
•
Hematology
How would you manage concomitant JAK2 MPN and BCR-ABL CML resistant to imatinib
Related Questions
Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?
What are common indications for ordering NGS of peripheral blood?
What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
Does your evaluation of a young person with spontaneous upper extremity DVT vary as compared to lower extremity DVT?
Would you offer bridging radiation before or after leukapheresis?
How would you approach choosing a regimen for a patient with multiple myeloma refractory to daratumumab and lenalidomide, with severe neuropathy from bortezomib?
What are your management strategies for malignant pericardial effusion with a high risk of spontaneous hemorrhage, particularly in patients requiring anticoagulation for chronic atrial fibrillation?
Have you encountered acute kidney injury after starting eltrombopag for aplastic anemia as part of triple immunosuppressive regimen with ATG and cyclosporine?
